PATENT CLAIM ANALYSIS

Application Number: 16083750
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["514", "253070"]

Abstract:
Methods of using the antipsychotic drug aripiprazole in treating a neurodegenerative disease such as Machado-Joseph disease/Spinocerebellar ataxia type 3 (MJD/SCA3) are disclosed. The methods comprise administering aripiprazole in an amount effect to decrease protein aggregates in the central nervous system and intracellular forms of pathogenic proteins such as mutant ataxin-3.

Claim (Index 3):
The method of  claim 1  or  claim 2 , comprising administering aripiprazole in an amount effective to decrease protein aggregates in an area of the central nervous system of the subject selected from the brainstem, cerebellum, spinal cord, forebrain, and combinations thereof.

Metadata:
- Claim Count in Document: 36.0
- Percentile: 97.0
- Lexical Diversity: 1.17391
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14585607', '15761964', '15895877', '13936696', '15554679']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7655003830243324
- 35 USC 102 Novelty (BERT): 0.5224036876698261
- Combined Prediction Score: 0.7411907134888818
- Mean Citation Score: 262.901052
- Max Citation Score: 323.41345
- Similarity Product: 231.49693378989105

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test